Skip to main content

Syneos Health Responds to COVID-19 Public Health Challenge by Joining Call to Action to Activate Clinically-Qualified Healthcare Professionals

Written by Customer Service on . Posted in Public Companies.

Alongside ACRO, Syneos Health to Provide Support for COVID-19 Testing Centers;
Company Continues Public Service Educational Program to Address Ventilator Shortage MORRISVILLE, N.C., April 03, 2020 (GLOBE NEWSWIRE) — Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a volunteer program to enable clinically-qualified employees to address the UK government’s call for volunteers to support COVID-19 testing.  Syneos Health joins the effort, supported by the Association of Clinical Research Organizations (ACRO), to help the UK identify 2,000 clinically-qualified volunteers to administer throat and nasal swab tests at COVID-19 testing centers being established throughout the country. The Company has extended the volunteer program worldwide to enable medical professionals who are called on by local governments to participate in COVID-19 support efforts, in accordance with country-specific guidelines. Syneos Health’s 24,000 employees worldwide, include thousands of medically trained professionals with frontline healthcare expertise including doctors, nurses, infectious disease experts, and lab technicians.“We’re honored to be able to support the heroic frontline workers battling this pandemic, and are extremely proud of our courageous employees and fellow industry colleagues who are stepping up to care for patients,” said Alistair Macdonald, Chief Executive Officer of Syneos Health and Chair, ACRO. “Coming together with our communities now – by bringing forward our expertise, contacts and resources – will allow us to all come back stronger together.”The volunteer program follows on the heels of the Company’s public service educational Ventilator Initiative, launched to raise awareness of invasive bi-level positive airway pressure (BiPAP) machines – using BiPAP machines already available in most hospitals – to delay or remove the need for mechanical ventilation for intubated COVID-19 patients. The program is supported by clinical and commercial leaders from across the organization with infectious disease, respiratory, critical care, and medical education and training expertise.BiPAP devices are now an acknowledged bridging option for COVID-19 patients in need of ventilation, with the FDA and American Association for Respiratory Care issuing guidance providing for the use of these devices on an emergency basis. New York State Governor Andrew Cuomo also announced the purchase of 3,000 BiPAP machines this week. This option is also gaining visibility from metro and regional media – WABC 11 TV, Triangle Business Journal and WRAL Techwire – as health systems prepare for the shortage of mechanical ventilators and more and more healthcare professionals may be required to treat outside of their specialty,“It’s inspiring to see our employees around the world determined to connect and passionate about community, even as COVID-19 keeps us apart,” said Macdonald.  “We are seeing the same strength, resiliency and spirit in our customers, industry colleagues and global communities as we all pull together to keep each other safe and moving forward.”Visit www.COVID-BiPAPinfo.com to learn, share, and spread the news about this much needed public health solution.About Syneos HealthSyneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Syneos Health brings together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. The Company shares insights, uses the latest technologies, and applies advanced business practices to speed its customers’ delivery of important therapies to patients. To learn more about how Syneos Health is shortening the distance from lab to life® visit syneoshealth.com.Investor Relations Contact:Ronnie Speight
Senior Vice President, Investor Relations
Phone: +1 919 745 2745
Email: Investor.Relations@syneoshealth.com    Press/Media Contact:Danielle DeForge
Executive Director, External Communications
Phone: +1 781 425 2624
Email: danielle.deforge@syneoshealth.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.